In The Lancet Diabetes & Endocrinology, Gastaldelli and colleagues present their findings from the SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial (1). It is the first study to date to assess the effect of a 52-week treatment with once-weekly subcutaneous tirzepatide versus once-daily insulin deglutec on liver fat content (LFC) in patients with inadequately controlled type 2 diabetes (1). A total of 296 participants without a history of significant alcohol consumption were randomised to active treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; insulin degludec, n=74). The primary efficacy endpoint was the change from baseline in LFC as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 52, using pooled data from tirzepatide 10 and 15 mg arms versus insulin degludec. [....]
Tirzepatide adds hepatoprotection to its armoury
Targher, Giovanni
2022-01-01
Abstract
In The Lancet Diabetes & Endocrinology, Gastaldelli and colleagues present their findings from the SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial (1). It is the first study to date to assess the effect of a 52-week treatment with once-weekly subcutaneous tirzepatide versus once-daily insulin deglutec on liver fat content (LFC) in patients with inadequately controlled type 2 diabetes (1). A total of 296 participants without a history of significant alcohol consumption were randomised to active treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; insulin degludec, n=74). The primary efficacy endpoint was the change from baseline in LFC as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at week 52, using pooled data from tirzepatide 10 and 15 mg arms versus insulin degludec. [....]
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
